Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(20%)
Results Posted
33%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph not_applicable
4
40%
Ph phase_1
3
30%
Ph phase_3
2
20%
Ph early_phase_1
1
10%

Phase Distribution

4

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
3(30.0%)
Phase 3Large-scale testing
2(20.0%)
N/ANon-phased studies
4(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Not yet recruiting3
Recruiting2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 13 (30.0%)
Phase 32 (20.0%)
N/A4 (40.0%)

Trials by Status

withdrawn110%
terminated110%
recruiting220%
completed330%
not_yet_recruiting330%

Recent Activity

2 active trials
Showing 5 of 10
not_yet_recruitingphase_3

Effect of Tributyrin Supplementation on Glycemic Control, Inflammation, and Cardiovascular Risk in Patients With Type 2 Diabetes

NCT07503548
recruitingnot_applicable

The Metabolic Effects of Oral Tributyrin Administration

NCT07463495
not_yet_recruitingphase_3

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

NCT06797817
recruitingphase_1

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

NCT07154511
not_yet_recruitingnot_applicable

ButOx Human Trial: An Open Label Prospective Cohort Study to Investigate the Effect of Tributyrin (Butyrate Precursor Molecule) Supplementation on Markers of Calcium Oxalate Nephrolithiasis

NCT07004257
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07503548Phase 3

Effect of Tributyrin Supplementation on Glycemic Control, Inflammation, and Cardiovascular Risk in Patients With Type 2 Diabetes

Not Yet Recruiting
NCT07463495Not Applicable

The Metabolic Effects of Oral Tributyrin Administration

Recruiting
NCT06797817Phase 3

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Not Yet Recruiting
NCT07154511Phase 1

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

Recruiting
NCT07004257Not Applicable

ButOx Human Trial: An Open Label Prospective Cohort Study to Investigate the Effect of Tributyrin (Butyrate Precursor Molecule) Supplementation on Markers of Calcium Oxalate Nephrolithiasis

Not Yet Recruiting
NCT05446168Phase 1

Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation

Terminated
NCT06700785Not Applicable

A Pharmacokinetic Comparison of Three Butyrate Products

Completed
NCT05951153Early Phase 1

Tributyrin to Promote Gut Health Among Children Undergoing Hematopoietic Cell Transplantation

Withdrawn
NCT00002677Phase 1

Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors

Completed
NCT02264951Not Applicable

Fat-induced Release of GLP-1 in Humans

Completed

All 10 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
10